Carregant...
AT-07 A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL
BACKGROUND: Ependymoma is an uncommon primary CNS tumor in adults, with no standardized treatment at recurrence. Little is known of the symptom burden associated with potential treatments. CERN-0802 combined lapatinib (targets ErbB1, ErbB2) with dose-dense temozolomide for patients with recurrent di...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4217844/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|